US Patent

US11154553 — Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function

Method of Use · Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2033-09-24 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of starting aripiprazole treatment in patients with impaired CYP2D6 or CYP3A4 enzyme function.

USPTO Abstract

The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.

Drugs covered by this patent

Abilify (aripiprazole) · Generic (originally Otsuka/BMS)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1632`	—	Abilify
`U-1632`	—	Abilify
`U-1632`	—	Abilify
`U-1632`	—	Abilify

Patent Metadata

Patent number: US11154553
Jurisdiction: US
Classification: Method of Use
Expires: 2033-09-24
Drug substance claim: No
Drug product claim: No
Assignee: Otsuka Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.